S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.43
0.0%
$39.38
$6.71
$64.57
$4.23B1.143.81 million shs2.46 million shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$0.79
-3.7%
$0.89
$0.67
$3.13
$59.45M0.47872,920 shs539,990 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$1.41
-0.7%
$1.60
$1.35
$3.87
$53.61M1.57197,164 shs79,920 shs
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$3.53
$1.12
$11.30
$96.26M2.274.33 million shs1.20 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-0.05%+0.05%+61.28%+224.75%+763.67%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-3.55%-8.11%-9.55%-5.11%-68.50%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-1.06%-12.19%-2.43%-23.22%-55.96%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
1.5051 of 5 stars
2.13.00.00.03.24.20.0
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
3.9503 of 5 stars
3.22.00.04.62.41.71.3
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.8468 of 5 stars
3.52.00.00.03.60.81.9
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
2.27
Hold$50.33-21.88% Downside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$11.001,296.65% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
3.00
Buy$15.00967.62% Upside
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest SCYX, KZR, ALPN, and SNSS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/12/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
4/9/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
4/1/2024
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
3/19/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$58.88M71.73N/AN/A$5.64 per share11.42
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M8.19N/AN/A$2.58 per share0.31
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$140.14M0.38$1.87 per share0.75$1.96 per share0.72
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$2.07M0.00N/AN/A$1.42 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$67.04M$1.321.06N/AN/A47.84%156.27%71.00%5/9/2024 (Estimated)
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
-$23.33M-$2.70N/AN/AN/AN/A-179.05%-72.27%N/A

Latest SCYX, KZR, ALPN, and SNSS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million
3/14/2024Q4 2023
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$0.39-$0.35+$0.04-$0.26N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/A
7.86
7.86
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.05
11.66
11.66
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.17
6.26
6.26
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/A
7.74
7.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
75.17%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
28.41%

Insider Ownership

CompanyInsider Ownership
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
42.30%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
7.90%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.40%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
4.22%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
14265.55 million37.82 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
5872.80 million67.05 millionNot Optionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2937.75 million36.09 millionOptionable
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
2418.09 millionN/AOptionable

SCYX, KZR, ALPN, and SNSS Headlines

SourceHeadline
AQSZF Aequus Pharmaceuticals Inc.AQSZF Aequus Pharmaceuticals Inc.
seekingalpha.com - December 20 at 5:25 AM
4 Breakout Stocks to Watch Going Into Labor Day4 Breakout Stocks to Watch Going Into Labor Day
thestreet.com - August 6 at 7:27 PM
4 Stocks Under $10 to Trade Now4 Stocks Under $10 to Trade Now
thestreet.com - January 14 at 10:56 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alpine Immune Sciences logo

Alpine Immune Sciences

NASDAQ:ALPN
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Kezar Life Sciences logo

Kezar Life Sciences

NASDAQ:KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
SCYNEXIS logo

SCYNEXIS

NASDAQ:SCYX
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Sunesis Pharmaceuticals logo

Sunesis Pharmaceuticals

NASDAQ:SNSS
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.